 |
1 Disease |  |
0 Trials |
|
0 Trials |  |
22 News |  |
- | FB3001 / Frontier Biotech
Journal: Characterization of atypical pathogenic Aeromonas salmonicida isolated from a diseased Siberian sturgeon (Acipenser baerii). (Pubmed Central) - Jul 24, 2023
Antibiotic sensitivity testing showed that the strain is sensitive to aminoglycosides, amphenicols, nitrofurans, quinolones, and tetracyclines. Half-lethal doses (LD) of strain AB001 for Oreochromis mossambicus and A. baerii were determined: respectively 1.7
- | FB3001 / Frontier Biotech
Journal: Impact of a Single Dose of a Probiotic Nutritional Supplement (AB001) on Absorption of Ethylalcohol: Results From a Randomized Double-Blind Crossover Study. (Pubmed Central) - Jan 24, 2023
The supplement uptake was well tolerated and there were no adverse events related to the study intervention. Uptake of a single dose of AB001 shortly before drinking alcohol significantly reduced plasma alcohol and breath alcohol concentrations, but the effect was less pronounced compared to chronic uptake as shown previously.
- | FB3001 / Frontier Biotech
Journal: Chronic Uptake of A Probiotic Nutritional Supplement (AB001) Inhibits Absorption of Ethylalcohol in the Intestine Tract - Results from a Randomized Double-blind Crossover Study. (Pubmed Central) - Jul 1, 2022
One week of supplementation with AB001 resulted in a substantially reduced absorption of alcohol into the body. Regular uptake of AB001 may help to prevent liver and other organ damage, and may reduce the negative medical and economical impact of social drinking on the individual and the society.
- | ProCase (AB002) / Aronora, AB001 for pain / Frontier Biotech
Journal, IO biomarker: Dual mechanisms of novel CD73-targeted antibody and antibody-drug conjugate in inhibiting lung tumor growth and promoting antitumor immune-effector function. (Pubmed Central) - Jan 21, 2022
Studies with human PBMC-derived systems confirmed CD73-ADC as fully functional in protecting effector T cells and stimulating DCs thus providing dual benefits in killing CD73-high tumors and improving cancer immunity response. These results warrant clinical investigation of CD73-targeted antibody and ADC for treating advanced lung cancer.
- || FB3001 / Frontier Biotech
Trial completion: Tolerability, Safety and Pharmacokinetics of a Topical AB001 Patch in Healthy Subjects (clinicaltrials.gov) - Mar 30, 2020
P1, N=34, Completed, Sponsor: Frontier Biotechnologies Inc.
These results warrant clinical investigation of CD73-targeted antibody and ADC for treating advanced lung cancer. Recruiting --> Completed
- || FB3001 / Frontier Biotech
Enrollment open: Tolerability, Safety and Pharmacokinetics of a Topical AB001 Patch in Healthy Subjects (clinicaltrials.gov) - Jul 5, 2019
P1, N=34, Recruiting, Sponsor: Frontier Biotechnologies Inc.
Recruiting --> Completed Not yet recruiting --> Recruiting
- || FB3001 / Frontier Biotech
New P1 trial: Tolerability, Safety and Pharmacokinetics of a Topical AB001 Patch in Healthy Subjects (clinicaltrials.gov) - Jun 24, 2019
P1, N=34, Not yet recruiting, Sponsor: Frontier Biotechnologies Inc.
- |||| FB3001 / Frontier Biotech
Trial completion: A Study of a Topical Patch (AB001) in Patients With Chronic Low Back Pain (clinicaltrials.gov) - Sep 3, 2015
P2, N=146, Completed, Sponsor: Frontier Biotechnologies Co., Ltd.
Not yet recruiting --> Recruiting Recruiting --> Completed
- | FB3001 / Frontier Biotech
New P2 trial: A Study of a Topical Patch (AB001) in Patients With Chronic Low Back Pain (clinicaltrials.gov) - May 7, 2015
P2, N=142, Recruiting, Sponsor: Frontier Biotechnologies Co., Ltd.